The (Flip and Fix) Internal Limiting Flap Technique Versus the Classic Temporal Flap for Macular Hole Repair (Flip and Fix)

May 29, 2024 updated by: Islam Shereen Hamdy, Alexandria University

Purpose To describe a novel technique of MH repair and compare it to the perfluorocarbon liquid (PFCL) assisted temporal ILM flap technique.

Methods Twenty-two eyes of 22 patients with MH were randomized on 1:1 basis into two groups. Group A cases were treated using the (Flip and Fix) technique in which the single-layer ILM flap was (flipped), flattened over the macula using PFCL and (fixed) in place using 2 drops of autologous non-heparinized blood over the superonasal and the inferonasal edges of the flap (away from the MH center). Group B patients had the classic temporal ILM flap technique without using the PFCL or autologous blood. All patients were followed up for a period of 6 months after the surgery.

Results No significant difference was observed in initial and final visual acuities between Groups A and B. Intraoperative flap displacement and did not occur in Group A and occurred in 2 eyes in Group B (18.2%) one of them showed failed MH closure and required reoperation, These 2 cases had a final (W shape) MH closure and a worse final vision than the remaining cases which had either (U shape) or (V shape) final MH closure.

Conclusions The study results show that the (Flip and Fix) technique is as effective as the PFCL-assisted temporal ILM flap technique and is associated with less ILM flap displacement risk for the repair of macular holes.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

We conducted a prospective randomized comparative interventional study in which we enrolled patients older than 50 years with idiopathic macular holes who presented to (Removed in the blinded version of manuscript) in the period between February 2021 and February 2022. Patients with previous macular surgeries and those with any other significant macular pathologies e.g., diabetic macular oedema, myopic maculopathy, choroidal neovascular membrane, or macula-off retinal detachment were excluded.

The study protocol was reviewed and approved by the Ethics Committee of (Removed in the blinded version of manuscript). All patients signed an informed consent after explaining the procedures. The study was conducted in accordance with the tenets of the Declaration of Helsinki.

For all the patients, a retina consultant (I. A.) masked to the procedure that will be done for the patient conducted a comprehensive ophthalmic examination, including best-corrected visual acuity (BCVA) (measured using the Snellen's chart and then converted to the LogMAR for the statistical analysis), slit-lamp examination, and fundus examination.

All the patients had a pre-operative macular OCT scan done. The scans were assessed by the masked retina consultant (I. A.) to confirm the diagnosis and to measure the minimum MH diameter.

The included patients were randomized by a research nurse on a 1:1 basis using the closed envelope technique to have either the new (Flip and fix) technique (Group A) or the PFCL assisted temporal inverted ILM flap technique (Group B).

All the surgeries were done under general anaesthesia by a single surgeon (M. A.) using a wide-angle viewing non-contact system (Resight; Carl Zeiss Meditec AG, Jena, Germany) and 23 Gauge Alcon Constellation vitrectomy machine (Alcon Laboratories, Fort Worth, TX) to complete the core vitrectomy and induction of the posterior vitreous detachment if not already detached, this was followed by an injection the Brilliant Blue G (Tissueblue 0.025% DORC, Zuidland, The Netherland) to stain the ILM.

In both groups, a single-layer ILM temporal flap of approximately 2 times the size of the optic disc was fashioned using an ILM forceps temporal to the macula. The nasal edge of the flap was not detached from the temporal MH edge. The flap was reflected nasally to cover the MH In the (Flip and Fix) technique group, the (flipped) ILM flap was secured in place and flattened over the macular surface using a 1.5 cc bubble of PFCL (Arcaline; Arcadophtha, Toulouse, France) injected over the flipped ILM flap. Then fluid air exchange with removal of the PFCL bubble was done followed by (fixing) the ILM flap over the macular surface using two drops of autologous non-heparinized blood -collected by the attending nurse or anaesthesiologist from one of the veins on the dorsum of the hand- one dropped over the superior-nasal and another at the inferior-nasal edges of the ILM flap (away from the MH center). On the other hand, in the classic temporal ILM flap group, PFCL and blood were not used to fix the ILM flap. Videos demonstrating the technique are provided as supplemental files 1 and 2.

In both groups, at the conclusion of the surgery the air was exchanged for a non-expansile concentration (20%) of sulphur hexafluoride gas SF6 and the patient was asked to maintain a face -down position for 5 days postoperatively. The surgical steps of the (flap and fix) technique are summarized in Figure 1.

For all the cases, intraoperative ILM flap displacement (defined as a significant displacement of the inverted ILM flap after its initial positioning over the MH that necessitated readjustment) was reported by the operating surgeon.

All the patients were examined postoperatively at 1, 3, and 6 months by a retina consultant masked to the used surgical procedure (I. A). The best corrected visual acuity, slit-lamp examination, fundus examination and macular OCT scanning were done in each postoperative visit.

According to the cross-sectional morphology on the postoperative macular OCT scan, foveal contour was classified into one of the following categories: U-shape, V-shape, and W-shape (irregular). The presence of a thin hyperreflective band of tissue extending on both sides of the previous MH Flap between the inner surface of the retina was assessed and considered a (membranous i.e., flap closure).

The data about the pre-operative MH base size, minimum MH diameter, BCVA, post-operative closure rate, BCVA, and the pattern of the MH closure was collected.

Study Type

Interventional

Enrollment (Actual)

22

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Alexandria, Egypt
        • Faculty of Medicine Alexandria University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria: patients with idiopathic macular holes who presented to (Removed in the blinded version of manuscript) in the period between February 2021 and February 2022.

Exclusion Criteria: Patients with previous macular surgeries and those with any other significant macular pathologies e.g., diabetic macular oedema, myopic maculopathy, choroidal neovascular membrane, or macula-off retinal detachment -

-

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Triple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Flip and fix ILM flap
In the (Flip and Fix) technique group, the (flipped) ILM flap was secured in place and flattened over the macular surface using a 1.5 cc bubble of PFCL (Arcaline; Arcadophtha, Toulouse, France) injected over the flipped ILM flap. Then fluid air exchange with removal of the PFCL bubble was done followed by (fixing) the ILM flap over the macular surface using two drops of autologous non-heparinized blood -collected by the attending nurse or anaesthesiologist from one of the veins on the dorsum of the hand- one dropped over the superior-nasal and another at the inferior-nasal edges of the ILM flap (away from the MH center).
In both groups, a single-layer ILM temporal flap of approximately 2 times the size of the optic disc was fashioned using an ILM forceps temporal to the macula. The nasal edge of the flap was not detached from the temporal MH edge. The flap was reflected nasally to cover the MH
Active Comparator: classic temporal ILM flap
PFCL and blood were not used to fix the ILM flap
In both groups, a single-layer ILM temporal flap of approximately 2 times the size of the optic disc was fashioned using an ILM forceps temporal to the macula. The nasal edge of the flap was not detached from the temporal MH edge. The flap was reflected nasally to cover the MH

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Macular hoe closure by OCT scan
Time Frame: 1, 3, and six months postoperatively
Macular OCT scan was used to assess the MH closure
1, 3, and six months postoperatively
LogMAR visual acuity
Time Frame: 1, 3, and six months postoperatively
Best corrected visual acuity was assessed using the LogMAR vision
1, 3, and six months postoperatively

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Islam SH Ahmed, M.D., University of Alexandria

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

February 1, 2021

Primary Completion (Actual)

February 1, 2022

Study Completion (Actual)

February 1, 2023

Study Registration Dates

First Submitted

May 29, 2024

First Submitted That Met QC Criteria

May 29, 2024

First Posted (Estimated)

June 4, 2024

Study Record Updates

Last Update Posted (Estimated)

June 4, 2024

Last Update Submitted That Met QC Criteria

May 29, 2024

Last Verified

May 1, 2024

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

The data are available upon request

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Hacular Hole Repair

Clinical Trials on Vitrectomy with ILM flap

3
Subscribe